AR and prostate cancer: For example, in prostate cancer, Kallikrein-related peptidase 3 eRNA (KLK3e), an eRNA produced by KLK3’s upstream enhancers, can selectively enhance the androgen receptor (AR)-dependent gene expression, resulting in a positive effect on prostate cancer cell proliferation (Hsieh et al., 2014).